Prevention and treatment of osteoporosis in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 12, Issue 8, 2006, Pages 797-813

  Lichtenstein, Gary R ^a,c   Sands, Bruce E ^b   Pazianas, Michael ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CCFA Guidelines

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; AZATHIOPRINE; BUDESONIDE; CALCITONIN; CALCITRIOL; CALCIUM; CYCLOSPORIN A; ESTROGEN; ETIDRONIC ACID; GLUCOCORTICOID; HEPARIN; IBANDRONIC ACID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; TACROLIMUS; WARFARIN;

BONE DENSITY; BONE TURNOVER; BREAST CANCER; CLINICAL DECISION MAKING; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CROHN DISEASE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERITIS; ESTROGEN THERAPY; HOT FLUSH; HUMAN; HYPERCALCEMIA; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; OSTEOPOROSIS; OSTEOSARCOMA; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STANDARD; STROKE; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE REMODELING; CALCIUM, DIETARY; DENSITOMETRY, X-RAY; FRACTURES, SPONTANEOUS; GLUCOCORTICOIDS; HUMANS; INFLAMMATORY BOWEL DISEASES; OSTEOPOROSIS; RISK FACTORS; VITAMIN D;

EID: 33747418927     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/00054725-200608000-00016     Document Type: Review

References (179)

1. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut. 1987;28:410-415.
2. Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med. 1993;94:646-650.
3. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study group. World Health Organ Tech Rep Ser. 1994; 843:1-129.
4. Mundy GR, Chen D, Oyajobi BO. Bone remodeling. In: Primer on the Metabolic Bone Disorders and Disorders of Mineral Metabolism. 5th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2003:46-57.
5. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA. 2001;285:785-795.
6. Melton LJ, Chrischilles EA, Cooper C, et al. How many women have osteoporosis? J Bone Miner Res. 1992;9:1005-1010.
7. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser. 2003;921:1-164.
8. National Osteoporosis Foundation. Fast Facts on Osteoporosis. Available at: http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed November 21, 2005.
9. Silvennoinen JA, Karttunen TJ, Niemela SE, et al. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut. 1995;37:71-76.
10. Jahnsen J, Falch JA, Aadland E, et al. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut. 1997;40:313-319.
11. Robinson RJ, Al Azzawi F, Iqbal SJ, et al. The relation of hand skinfold thickness to bone mineral density in patients with Crohn's disease. Eur J Gastroenterol Hepatol. 1997;9:945-949.
12. Robinson RJ, Iqbal SJ, Abrams K, et al. Increased bone resorption in patients with Crohn's disease. Aliment Pharmacol Ther. 1998;12:699-705.
13. Schulte C, Dignass AU, Mann K, et al. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis. 1998;4:268-275.
14. Andreassen H, Hylander E, Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients. Am J Gastroenterol. 1999;94:824-828.
15. Dinca M, Fries W, Luisetto G, et al. Evolution of osteopenia in inflammatory bowel disease. Am J Gastroenterol. 1999;94:1292-1297.
16. Ardizzone S, Bollani S, Bettica P, et al. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med. 2000;247:63-70.
17. Schoon EJ, Blok BM, Geerling BJ, et al. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology. 2000;119:1203-1208.
18. Ulivieri FM, Piodi P, Taioli E, et al. Bone mineral density and body composition in ulcerative colitis: a six-year follow-up. Osteoporos Int. 2001;12:343-348.
19. Lamb EJ, Wong T, Smith DJ, et al. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:1895-1902.
20. Clements D, Motley RJ, Evans WD, et al. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. Scand J Gastroenterol. 1992;27:1055-1060.
21. Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci. 1992;37:1396-1403.
22. Ghosh S, Cowen S, Hannan WJ, et al. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology. 1994;107:1031-1039.
23. Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology. 1995;108:417-422.
24. Bernstein CN, Seeger LL, Sayre JW, et al. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res. 1995;10:250-256.
25. Roux C, Abitbol V, Chaussade S, et al. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int. 1995;5:156-160.
26. Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997;40:228-233.
27. Bischoff SC, Herrmann A, Goke M, et al. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol. 1997;92:1157-1163.
28. Pollak RD, Karmeli F, Eliakim R, et al. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93:1483-1490.
29. Lee SH, Kim HJ, Yang SK, et al. Decreased trabecular bone mineral density in newly diagnosed inflammatory bowel disease patients in Korea. J Gastroenterol Hepatol. 2000;15:512-518.
30. Bernstein CN, Leslie WD, Taback SP. Bone density in a population-based cohort of premenopausal adult women with early onset inflammatory bowel disease. Am J Gastroenterol. 2003;98:1094-1100.
31. Jahnsen J, Falch JA, Mowincke lP, et al. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol. 2002;37:192-199.
32. Staun M, Tjellesen L, Thale M, et al. Bone mineral content in patients with Crohn's disease: a longitudinal study in patients with bowel resections. Scand J Gastroenterol. 1997;32:226-232.
33. Robinson RJ, Al Azzawi F, Iqbal SJ, et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci. 1998;43:2500-2506.
34. Schoon EJ, van Nunen AB, Wouters RSME, et al. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol Suppl. 2000;232:43-47.
35. Habtezion A, Silverberg MS, Parkes R, et al. Risk factors for low bone density in Crohn's disease. Inflamm Bowel Dis. 2002;8:87-92.
36. Siffiledeen JS, Fedorak RN, SiminoskiK, et al. Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease. Inflamm Bowel Dis. 2004;10:220-228.
37. Stockbrugger RW, Schoon EJ, Bollani S, et al. Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Aliment Pharmacol Ther. 2002;16:1519-1527.
38. de Jong DJ, Corstens FH, Mannaerts L, et al. Corticosteroid-induced osteoporosis: does it occur in patients with Crohn's disease? Am J Gastroenterol. 2002;97:2011-2015.
39. Klaus J, Armbrecht G, Steinkamp M, et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut. 2002;51:654-658.
40. Siffledeen JS, Siminoski K, Steinhart H, et al. The frequency of vitamin D deficiency in adults with Crohn's disease. Can J Gastroenterol. 2003;17:473-478.
41. Teichmann J, Lange U, Stracke H, et al. Rapid spinal trabecular bone loss in female patients with ileitis terminalis Crohn and additional sacroiliac joint inflammation. Rheumatol Int. 1997;17:45-48.
42. Dresner-Pollak R, Karmeli F, Eliakim R, et al. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. Am J Gastroenterol. 2000;95:699-704.
43. Schulte C, Dignass AU, Mann K, et al. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Scand J Gastroenterol. 1999;34:696-702.
44. de Jong DJ, Mannaerts L, van Rossum LG, et al. Longitudinal study of bone mineral density in patients with Crohn's disease. Dig Dis Sci. 2003;48:1355-1359.
45. Jahnsen J, Falch JA, Mowinckel P, et al. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol. 2004;39:145-153.
46. Motley RJ, Clements D, Evans WD, et al. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Miner. 1993;23:95-104.
47. Silvennoinen J, Lamberg-Allardt C, Karkkainen M, et al. Dietary calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease. J Intern Med. 1996;240:285-292.
48. Reffitt DM, Meenan J, Sanderson JD, et al. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2003;15:1267-1273.
49. van Hogezand RA, Banffer D, Zwinderman AH, et al. Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease. Osteoporos Int. 2006;17:535-542.
50. Vogelsang H, Ferenci P, Woloszczuk W, et al. Bone disease in vitamin D-deficient patients with Crohn's disease. Dig Dis Sci. 1989;34:1094-1099.
51. Jensen MB, Houborg KB, Vestergaard P, et al. Improved physical performance and increased lean tissue and fat mass in patients with ulcerative colitis four to six years after ileoanal anastomosis with a J-pouch. Dis Colon Rectum. 2002;45:1601-1607.
52. Abitbol V, Roux C, Guillemant S, et al. Bone assessment in patients with ileal pouch-anal anastomosis for inflammatory bowel disease. Br J Surg. 1997;84:1551-1554.
53. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med. 2000;133:795-799.
54. Loftus EV Jr, Crowson CS, Sandborn WJ, et al. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology. 2002;123:468-475.
55. Loftus EV Jr, Achenbach SJ, Sandborn WJ, et al. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003;1:465-473.
56. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol. 2002;156:1-10.
57. Vestergaard P, Krogh K, Rejnmark L, et al. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut. 2000;46:176-181.
58. Card T, West J, Hubbard R, et al. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut. 2004;53:251-255.
59. van Staa TP, Cooper C, Brusse LS, et al. Inflammatory bowel disease and the risk of fracture. Gastroenterology. 2003;125:1591-1597.
60. Peacock M, Turner CH, Econs MJ, et al. Genetics of osteoporosis. Endocr Rev. 2002;23:303-326.
61. Econs MJ, Koller DL, Hui S L, et al. Confirmation of linkage to chromosome 1q for peak vertebral bone mineral density in premenopausal white women. Am J Hum Genet. 2004;74:223-228.
62. Peacock M, Koller DL, Hui S, et al. Peak bone mineral density at the hip is linked to chromosomes 14q and 15q. Osteoporos Int. 2004;15:489-496.
63. de Ronde W, Pols HA, van Leeuwen JP, et al. The importance of oestrogens in males. Clin Endocrinol (Oxf). 2003;58:529-542.
64. Stone KL, Seeley DG, Lui LY, et al. for the Osteoporotic Fractures Research Group. BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J Bone Miner Res. 2003;18:1947-1954.
65. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-1259.
66. Schulte CNS, Dignass AU, Goebell H, et al. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology. 2000;119:909-920.
67. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling-emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332:305-311.
68. Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor related protein 5 gene results in the autosomal dominant high bone-mass trait. Am J Hum Genet. 2002;70:11-19.
69. Gong Y, Slee RB, Fukai N, et al. for the Osteoporosis-Pseudoglioma Syndrome Collaborative Group. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;16:513-523.
70. Lin CL, Moniz C, Chambers TJ, et al. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology. 1996;111:1263-1271.
71. Hyams JS, Wyzga N, Kreutzer DL, et al. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. J Pediatr Gastroenterol Nutr. 1997;24:289-295.
72. Sylvester FA, Wyzga N, Hyams JS, et al. Effect of Crohn's disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res. 2002;17:695-702.
73. Fuss IJ. Cytokine network in inflammatory bowel disease. Curr Drug Targets Inflamm Allergy. 2003;2:101-112.
74. Franchimont N, Putzeys V, Collette J, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther. 2004;20:607-614.
75. Ryan BM, Russel MG, Schurgers L, et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment Pharmacol Ther. 2004;20:851-857.
76. Pazianas M, Rhim AD, Weinberg AM, et al. The effect of anti-TNFα therapy on spinal bone mineral density in patients with Crohn's disease. Ann NY Acad Sci. 2006;1068:543-546.
77. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol. 2005;100:2031-2035.
78. Eastwood JB, Pazianas M. Calcium and phosphate metabolism. In: Willkinson R, Jamison R, eds. Nephrology. London, UK: Chapman & Hall; 1997:358-368.
79. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487-501.
80. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology. 2005;115:1-20.
81. Ashcroft AJ, Cruickshank SM, Croucher PI, et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity. 2003;19:849-861.
82. Bernstein CN, Sargent M, Leslie WD. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. Inflamm Bowel Dis. 2005;11:325-330.
83. Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut. 2005;54:479-487.
84. Kong Y-Y, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteroclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-323.
85. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:65-176.
86. +CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut. 2005;54:78-86.
87. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990;112:352-364.
88. Alesci S, De Martino MU, Ilias I, et al. Glucocorticoid-induced osteoporosis: from basic mechanisms to clinical aspects. Neuroimmunomodulation. 2005;12:1-19.
89. Shaker JL, Lukert BP. Osteoporosis associated with excess glucocorticoids. Endocrinol Metab Clin North Am. 2005;34:341-356.
90. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.
91. Hodsman AB, Toogood JH, Jennings B, et al. Differential effect of inhaled budesonide and oral prednisolone on serum osteocalcin. J Clin Endocrinol Metab. 1991;72:530-540.
92. Lo-Cascio V, Bonucci E, Imbimbo B, et al. Bone loss after glucocorticoid therapy. Calcif Tiss Int. 1984;36:435-438.
93. van Staa TP, Abenhaim L, Cooper C, et al. Public health impact of adverse bone effects of oral corticosteroids. Br J Clin Pharmacol. 2001;51:601-607.
94. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J BoneMiner Res. 2004;19:893-899.
95. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with systemic and topical corticosteroids. J Intern Med. 2005;257:374-384.
96. Compston JE, Creamer B. Plasma levels and intestinal absorption of 25-hydroxy vitamin D in patients with small intestinal resections. Gut. 1977;18:171-175.
97. Madden AM, Morgan MY. The potential role of dual-energy X-ray absorptiometry in the assessment of body composition in cirrhotic patients. Nutrition. 1997;13:40-45.
98. Haderslev KV, Jeppesen PB, Sorensen HA, et al. Vitamin D status and measurements of markers of bone metabolism in patients with small intestinal resection. Gut. 2003;52:653-658.
99. Andreassen H, Rix M, Brot C, et al. Regulators of calcium homeostasis and bone mineral density in patients with Crohn's disease. Scand J Gastroenterol. 1998;33:1087-1093.
100. ISCD 2005 Official Positions. Available at: http://www.iscd.org/Visitors/ pdfs/ISCD_OP2005.pdf. Accessed on July 1, 2006.
101. Smith CB, Smith DA. Relations between age, mineral density and mechanical properties of human femoral compacta. Acta Orthop Scand. 1976;47:496-502.
102. Faulkner KG. The tale of the T-score: review and perspective. Osteoporos Int. 2005;16:347-352.
103. Madden AM, Morgan MY. The potential role of dual-energy X-ray absorptiometry in the assessment of body composition in cirrhotic patients. Nutrition. 1997;13:40-45.
104. Byrne TA, Morrissey TB, Gatzen C, et al. Anabolic therapy with growth hormone accelerates protein gain in surgical patients requiring nutritional rehabilitation. Ann Surg. 1993;218:400-416.
105. Kanis JA, Adami S. Bone loss in the elderly. Osteoporos Int. 1994;4(suppl 1):S59-S65.
106. Svendsen OL, Hassager C, Skodt V, et al. Impact of soft tissue on in vivo accuracy of bone mineral measurements in the spine, hip, and forearm: a human cadaver study. J Bone Miner Res. 1995;10:868-873.
107. Lenchik L, Watts NB. Regression to the mean: what does it mean? Using bone density results to monitor treatment of osteoporosis. J Clin Densitom. 2001;4:1-4.
108. LeBoff MS, Fuleihan GE, Angell JE, et al. Dual-energy x-ray absorptiometry of the forearm: reproducibility and correlation with single-photon absorptiometry. J Bone Miner Res. 1992;7:841-846.
109. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of BMD predict occurrence of osteoporosis fractures. BMJ. 1996;312:1254-1259.
110. Grampp S, Genant HK, Mathur A, et al. Comparisons of non-invasive bone mineral measurements in assessing age related loss, fracture discrimination and diagnosis classification. J Bone Miner Res. 1997;12:697-711.
111. Patel R, Blake GM, Fogelman I. An evaluation of the United Kingdom National Osteoporosis Society position statement on the use of peripheral dual-energy X-ray absorptiometry. Osteoporos Int. 2004;15:497-504.
112. Frost HM. Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res. 1969;3:211-237.
113. Boonen S, Kaufman JM, Réginster JY, et al. Patient assessment using standardized bone mineral density values and a national reference data base. Osteoporos Int. 2003;14:110-115.
114. Glüer CC, Eastell R, Reid DM, et al. Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study. J Bone Miner Res. 2004;19:782-793.
115. Fries W, Dinca M, Luisetto G, et al. Calcaneal ultrasound bone densitometry in IBD: a comparison with double X-ray densitometry of the lumbar spine. Am J Gastroenterol. 1998;93:2339-2344.
116. Jahnsen J, Falch JA, Mowinckel P, et al. Ultrasound measurements of calcaneus for estimation of skeletal status in patients with IBD. Scand J Gastroenterol. 1999;34:790-797.
117. Robinson RJ, Carr I, Iqbal SJ, et al. Screening for osteoporosis in Crohn's disease: a detailed evaluation of calcaneal ultrasound. Eur J Gastroenterol Hepatol. 1998;10:137-140.
118. Schwartz DA, Connolley CD, Koyama T, et al. Calcaneal ultrasound bone densitometry is not a useful tool to screen patients with inflammatory bowel disease at high risk for metabolic bone disease. Inflamm Bowel Dis. 2005;11:749-754.
119. von Tirpitz C, Klaus J, Steinkamp M, et al. Quantitative ultrasound of the proximal phalanges and dual-energy X-ray absorptiometry in Crohn's disease patients with osteopenia. J Gastroenterol. 2003;38:238-243.
120. Baran DT, Faulkner KG, Genant HK, et al. Diagnosis and management of osteoporosis: guidelines for the utilization of bone densitometry. Calcif Tissue Int. 1997;61:433-440.
121. Khosla S, Kleerekoper M. Biochemical markers of bone turnover. In: Primer on the Metabolic Bone Disorders and Disorders of Mineral Metabolism. 5th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2003:166-172.
122. Looker AC, Bauer DC, Chesnut CH III, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporosis Int. 2000;11:467-480.
123. Melton LJ III, Khosla S, Atkinson EJ, et al. Relationship of bone turnover to bone density and fractures. J Bone Miner Res. 1997;12:1083-1091.
124. Chesnut CH 3rd, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med. 1997;102:29-37.
125. Greenspan SL, Parker RA, Ferguson L, et al. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res. 1998;13:1431-1438.
126. Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab. 2000;85:3537-3540.
127. Trebble TM, Wootton SA, Stroud MA, et al. Laboratory markers predict bone loss in Crohn's disease: relationship to blood mononuclear cell function and nutritional status. Aliment Pharmacol Ther. 2004;19:1063-1071.
128. Dobnig H, Hofbauer LC, Viereck V, et al. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int. 2006;17:693-703.
129. Andreassen H, Rungby J, Dahlerup JF, et al. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol. 1997;32:1247-1255.
130. De Vos M, De Keyser F, Mielants H, et al. Bone and joint diseases in inflammatory bowel disease. Aliment Pharmacol Ther. 1998;12:397-404.
131. Buchman AL. Bones and Crohn's: problems and solutions. Inflamm Bowel Dis. 1999;5:212-227.
132. Valentine JF, Sninsky CA. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol. 1999;94:878-883.
133. Raisz LG. Clinical practice: screening for osteoporosis. N Engl J Med. 2005;353:164-171.
134. Shea B, Wells G, Cranney A, et al. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev. 2002;23:552-559.
135. Papadimitropoulos E, Wells G, Shea B, et al. for the Osteoporosis Methodology and Research Advisory Group. Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23:560-569.
136. Gillespie WJ, Avenell A, Henry DA, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis (Cochrane Review). The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons.
137. Jackson RD, LaCroix AZ, Gass M, et al. for the Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669-683.
138. Nordin Need AG. Impact of calcium and vitamin D supplementation on fracture risk. Available at: http://www.bonekey-ibms.org/news/ hotpaper16Feb06comment. dtl. Accessed July 1, 2006.
139. Boonen S, Rizzoli R, Meunier PJ, et al. The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report. Osteoporos Int. 2004;15:511-519.
140. Yates AA, Schlicker SA, Suitor CW. Dietary reference intakes: the new basis for recommendations for calcium and related nutrients, B vitamins, and choline. J Am Diet Assoc. 1998;98:699-706.
141. Bernstein CN, Seeger LL, Anton PA, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with IBD: a pilot study. Aliment Pharmacol Ther. 1996;10:777-786.
142. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol and calcitonin. N Engl J Med. 1993;328:1747-1752.
143. Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis, IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23:570-577.
144. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003;9:2643-2658.
145. Cranney A, Welch V, Adachi JD, et al. Etidronate for treating and preventing postmenopausal osteoporosis. Cochrane Database Syst Rev. 2001;4:CD003376.
146. Cranney A, Wells G, Willan A, et al. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002;23:560-569.
147. Cranney A, Tugwell P, Adachi J, et al. for the Osteoporosis Methodology and Research Advisory Group. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23:517-523.
148. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with onceweekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005;20:141-151.
149. Hosking D, Adami S, Felsenberg D, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomized placebo-controlled study. Curr Med Res Opin. 2003;19:383-394.
150. Henderson S, Hoffman N, Prince RA. Double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol. 2006;101:119-123.
151. Haderslev KV, Tjellesen L, Sorensen HA, et al. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology. 2000;119:639-646.
152. Bartram SA, Peaston RT, Rawlings DJ, et al. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther. 2003;18:1121-1127.
153. Stokkers PC, Deley M, Van Der Spek M, et al. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease. Scand J Gastroenterol. 2006;41:200-204.
154. Bone HG, Hosking D, Devogelaer JP, et al. for the Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189-1199.
155. Raisz GL, Rodan GA. Pathogenesis of osteoporosis. Endocrinol Metab Clin North Am. 2003;32:15-24.
156. HofbauerLC, KhoslaS, DunstanCR, et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999;140:4367-4370.
157. Hughes DE, Dai A, Tiffee JC, et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med. 1996;2:1132-1136.
158. Lean JM, Davies T, Fuller K, et al. A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest. 2003;112:915-923.
159. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
160. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res. 1992;7:1063-1069.
161. Hall GM, Daniels M, Doyle DV, et al. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum. 1994;37:1499-1505.
162. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifene: results from a 3-year randomized clinical trial: Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-645.
163. Seeman E, Crans GG, Diez-Perez A, et al. Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int. 2006;17:313-316.
164. Chestnut CH III, Silverman S, Adriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med. 1998;339:292-299.
165. Cranney A, Welch V, Adachi JD, et al. Calcitonin for preventing and treating corticosteroid-induced osteoporosis: the Cochrane Collaboration. Cochrane Library. 2005;1:1-31.
166. Neer R, Arnaud C, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
167. Orwoll E, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9-17.
168. Lichtenstein GR. Approach to corticosteroid dependent and corticosteroid-refractory Crohn's disease. Inflamm Bowel Dis. 2001;7(suppl 1):S23-S29.
169. Bernstein CN, Leslie WD. Therapy insight: osteoporosis in inflammatory bowel disease-advances and retreats. Nat Clin Pract Gastroenterol Hepatol. 2005;2:232-239.
170. Recommendations for the prevention and treatment of glucocorticoidinduced osteoporosis: 2001 update: American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2001;44:1496-1503.
171. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis: Glucocorticoid-Induced Osteoporosis Intervention study group. N Engl J Med. 1998;339:292-299.
172. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44:202-211.
173. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67:277-285.
174. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42:2309-2318.
175. Ringe J, Dorst A, Faber H, et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int. 2003;14:801-807.
176. Adachi JD, Roux C, Pitt PI, et al. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. J Rheumatol. 2000;27:2424-2431.
177. Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: results of a randomized controlled clinical trial. J Clin Invest. 1998;102:1627-1633.
178. Rehman Q, Lang TF, Arnaud CD, et al. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int. 2003;14:77-81.
179. Gonzalez-Rey E, Varela N, Sheibanie AF, et al. Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. Proc Natl Acad Sci U S A. 2006;103:4228-423